BMJ open · 2024
Viral shedding of SARS-CoV-2 in body fluids associated with sexual activity: a systematic review and meta-analysis.
МетаанализСистематический обзорСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calvet Guilherme Amaral, Kara Edna, Gonsalves Lianne, Seuc Armando Humberto, de Oliveira Raquel de Vasconcellos Carvalhaes, Thwin Soe Soe, Gomez Ponce de León Rodolfo, Gámez Maité Cabrera, Peña Gilda Monteagudo, Pendás Bertha Victoria Rodríguez, Alzugaray Manuel Gómez, Carballo Gisel Ovies, Cala Duniesky Cintra, Guimarães Patrícia Machado Quintaes, Bonet Mercedes, Taylor Melanie, Thorson Anna, Kim Caron, Ali Moazzam, Broutet Nathalie
Аннотация
OBJECTIVE: To identify and summarise the evidence on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection and persistence in body fluids associated with sexual activity (saliva, semen, vaginal secretion, urine and faeces/rectal secretion).
ELIGIBILITY: All studies that reported detection of SARS-CoV-2 in saliva, semen, vaginal secretion, urine and faeces/rectal swabs.
INFORMATION SOURCES: The WHO COVID-19 database from inception to 20 April 2022.
RISK OF BIAS ASSESSMENT: The National Institutes of Health tools.
SYNTHESIS OF RESULTS: The proportion of patients with positive results for SARS-CoV-2 and the proportion of patients with a viral duration/persistence of at least 14 days in each fluid was calculated using fixed or random effects models.
INCLUDED STUDIES: A total of 182 studies with 10 023 participants.
RESULTS: The combined proportion of individuals with detection of SARS-CoV-2 was 82.6% (95% CI: 68.8% to 91.0%) in saliva, 1.6% (95% CI: 0.9% to 2.6%) in semen, 2.7% (95% CI: 1.8% to 4.0%) in vaginal secretion, 3.8% (95% CI: 1.9% to 7.6%) in urine and 31.8% (95% CI: 26.4% to 37.7%) in faeces/rectal swabs. The maximum viral persistence for faeces/rectal secretions was 210 days, followed by semen 121 days, saliva 112 days, urine 77 days and vaginal secretions 13 days. Culturable SARS-CoV-2 was positive for saliva and faeces.
LIMITATIONS: Scarcity of longitudinal studies with follow-up until negative results.
INTERPRETATION: SARS-CoV-2 RNA was detected in all fluids associated with sexual activity but was rare in semen and vaginal secretions. Ongoing droplet precautions and awareness of the potential risk of contact with faecal matter/rectal mucosa are needed.
PROSPERO REGISTRATION NUMBER: CRD42020204741.
ELIGIBILITY: All studies that reported detection of SARS-CoV-2 in saliva, semen, vaginal secretion, urine and faeces/rectal swabs.
INFORMATION SOURCES: The WHO COVID-19 database from inception to 20 April 2022.
RISK OF BIAS ASSESSMENT: The National Institutes of Health tools.
SYNTHESIS OF RESULTS: The proportion of patients with positive results for SARS-CoV-2 and the proportion of patients with a viral duration/persistence of at least 14 days in each fluid was calculated using fixed or random effects models.
INCLUDED STUDIES: A total of 182 studies with 10 023 participants.
RESULTS: The combined proportion of individuals with detection of SARS-CoV-2 was 82.6% (95% CI: 68.8% to 91.0%) in saliva, 1.6% (95% CI: 0.9% to 2.6%) in semen, 2.7% (95% CI: 1.8% to 4.0%) in vaginal secretion, 3.8% (95% CI: 1.9% to 7.6%) in urine and 31.8% (95% CI: 26.4% to 37.7%) in faeces/rectal swabs. The maximum viral persistence for faeces/rectal secretions was 210 days, followed by semen 121 days, saliva 112 days, urine 77 days and vaginal secretions 13 days. Culturable SARS-CoV-2 was positive for saliva and faeces.
LIMITATIONS: Scarcity of longitudinal studies with follow-up until negative results.
INTERPRETATION: SARS-CoV-2 RNA was detected in all fluids associated with sexual activity but was rare in semen and vaginal secretions. Ongoing droplet precautions and awareness of the potential risk of contact with faecal matter/rectal mucosa are needed.
PROSPERO REGISTRATION NUMBER: CRD42020204741.